Includes Conduit’s first composition of matter patent filing for AZD5658 and multiple new combination filings for AZD1656 and AZD5658Patents derived from AI-led analysis conducted in partnership with Sarborg Limited NAPLES, Fla. and CAMBRIDGE, United Kingdom, July 07, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit" or the “Company”) today announces the filing of four new patent applications relating to its key assets AZD1656 and AZD5658, including the Company’s first patent fi ...

NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 22, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound development, announces that, following confirmation of compliance with the Bid Price and Equity Requirements as detailed in the announcement dated May 21, 2025, the Company received formal notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company’s ...

NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 22, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound development, announces that, following confirmation of compliance with the Bid Price and Equity Requirements as detailed in the announcement dated May 21, 2025, the Company received formal notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company’s ...

Conduit regains compliance with Bid Price and Equity RequirementsCDT will continue to be listed and traded on The Nasdaq Stock Market NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 21, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound development, announced that the Company received formal notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company h ...

Core Insights - Conduit Pharmaceuticals has secured a composition of matter patent for its lead asset, AZD1656, from the Korean Intellectual Property Office, enhancing its global intellectual property position and facilitating clinical development and strategic partnerships [1][2] - The patent approval follows similar grants in the U.S., Japan, and Australia, indicating a robust international patent strategy that supports Conduit's growth in the Asia-Pacific pharmaceutical market [1][2] - The company aims to leverage its innovative approach to compound development, utilizing artificial intelligence and cybernetics, to create long-term value through global partnerships and licensing deals [2] Company Overview - Conduit Pharmaceuticals is a clinical-stage life science company focused on developing Phase 2-ready assets through an integrated platform-driven approach [2] - The leadership team, including Dr. Andrew Regan and Dr. Freda Lewis-Hall, emphasizes a departure from traditional pharmaceutical business models by seeking exits through third-party licensing after successful clinical trials [2]